© PR Newswire
05.12.2025
096530
LISTED
KOE
Seegene Establishes French Subsidiary to Expand European Footprint
News Preview
- France becomes Seegene's eighth overseas sales subsidiary and third in Europe, following Italy and Germany- The country ranks as Europe's second-largest molecular diagnostics market, driven by demand in sexually transmitted infections and gastrointestinal testing, and respiratory virus detection.- The new subsidiary is expected to accelerat...
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2025
096530
LISTED
KOE
Seegene Establishes French Subsidiary to Expand European Footprint
News Preview
- France becomes Seegene's eighth overseas sales subsidiary and third in Europe, following Italy and Germany- The country ranks as Europe's second-largest molecular diagnostics market, driven by demand in sexually transmitted infections and gastrointestinal testing, and respiratory virus detection.- The new subsidiary is expected to accelerat...
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2025
096530
LISTED
KOE
/C O R R E C T I O N -- Seegene Inc./
News Preview
In the news release, "Seegene Establishes French Subsidiary to Expand European Footprint", issued 05-Dec-2025 by Seegene Inc. over PR Newswire, we are advised by the company that the first sub-headline should read "France becomes Seegene's eighth overseas sales subsidiary and third in Europe, following Italy and Germany" rather than "France beco...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© EQS Newswire
05.12.2025
EUZ
LISTED
XETR
Reorganization of the Eckert & Ziegler Executive Board
News Preview
Berlin, 5 December 2025. The Supervisory Board of Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) has decided to reduce the size of the Executive Board from three to two members as of 1 January 2026. The contract of Frank Yeager, member of the Executive Board and responsible for the Isotope Products segment, will end as planned on 31 December 2......
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© EQS Newswire
05.12.2025
EUZ
LISTED
XETR
Neuordnung im Vorstand von Eckert & Ziegler
News Preview
Berlin, 5. Dezember 2025. Der Aufsichtsrat der Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) hat beschlossen, zum 1.1.2026 den Vorstand von drei auf zwei Mitglieder zu verkleinern. Der Vertrag von Frank Yeager, Vorstandsmitglied und verantwortlich für das Segment Isotope Products endet planmäßig zum 31.12.2025. Herr Yeager wird dem Segment Is......
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2025
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Net Asset Value(s)
News Preview
WORLDWIDE HEALTHCARE TRUST PLC
LEI: 5493003YBCY4W1IMJU04
NET ASSET VALUE
The estimated un-audited net asset val...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
05.12.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement
News Preview
Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction PHILADELPHIA, PA / ACCESS Newswire / December 5, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
1877
LISTED
HKSE
Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis
News Preview
BLA of Roconkibart (IL-17A) for the treatment of moderate to severe plaque psoriasis has been accepted by the NMPA...
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2025
CVS
LISTED
NYSE
CVS Health generates over $474 Billion in 2024 U.S. economic impact, supporting communities throughout the United States
News Preview
New report highlights the company's role as a top U.S. employer, investing in improving health and supporting local communitiesWOONSOCKET, R.I., Dec. 5, 2025 /PRNewswire/ -- CVS Health® (NYSE: CVS) today released its inaugural National Economic Impact Report demonstrating the positive economic impact that the company has in communities across the...
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
News Preview
New interim results from the EpiCom trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, suggest improvements in non-seizure outcomesEight abstracts, including four late-breaking abstracts, underscore Jazz's continued commitment to the epilepsy community and advancing the comprehensive treatment for r...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
ORNBV
LISTED
HEL
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS5 December 2025 at 17.00 EET ...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2025
STOK
LISTED
NASDAQ
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
News Preview
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced data presentations that further support the potential of zorevunersen, an investigational antisense oligonucleotide, as a disease-modifying m...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
05.12.2025
AMLX
LISTED
NASDAQ
Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial
News Preview
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the presentation of early safety and tolerability data from its Phase 1 LUMINA trial of AMX0114 and results from ongoing work characterizing biomarkers of AMX0114 target engagement at the 36th International Symposium on ALS/MND (MNDA) held from December 5-7 in...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2025
OWLT
LISTED
NYSE
Owlet Launches TGA-Approved Dream Sock™ in Australia & New Zealand, Expanding International Footprint and Bringing Trusted Pediatric Health Monitoring to More Families Worldwide
News Preview
Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announces that Dream Sock™ is now available for families across Australia and New Zealand. Dream Sock recently received approval from Australia’s Therapeutic Goods Administration (TGA), meeting rigorous medical device standards in the region. With th...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2025
HCA
LISTED
NYSE
HCA Healthcare Announces $4.8 Million Gift to Help Launch Pepperdine University’s School of Nursing
News Preview
HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading healthcare providers, today announced it will give $4.8 million to Pepperdine University to help launch the School of Nursing within the College of Health Science. This is part of HCA Healthcare’s greater commitment to helping address the national nursing shortage.
“We believe that inve...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2025
ZTS
LISTED
NYSE
Zoetis Receives Health Canada Approval for Portela™(relfovetmab injection) to Alleviate Pain Associated with Osteoarthritis in Cats
News Preview
Zoetis Inc. today announced that Health Canada has approved Portela™ (relfovetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in cats. Designed to provide three months of OA pain relief with a single injection, Portela targets anti-nerve growth factor (NGF), which is a key mediator of OA pain and inflammation.
In a...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2025
GH
LISTED
NASDAQ
Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present a total of 14 abstracts with its research collaborators from multiple studies demonstrating the value of its tissue-free liquid biopsy tests at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 9–12, 2025.
Oral presentations will highlight...
Themefolio
Profiler
Peergroup
© Newsfile
05.12.2025
OSTX
LISTED
XASE
OS Therapies Announces FDA PDUFA Waiver & EMA Grants Union Marketing Authorisation Eligibility
News Preview
U.S. FDA grants waiver of application fee for BLA Filing of OST-HER2Scheduled pre-Marketing Authorisation Application meeting with United Kingdom's Medicines and Healthcare products Regulatory Agency on December 8, 2025Scheduled Type C Meeting with United States Food & Drug Administration on December 11, 2025New York, New York--(Newsfile Corp....
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2025
45030
LISTED
XJPX
Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting
News Preview
- Presentations include pooled post-hoc analysis of the Phase 3 ADMIRAL and COMMODORE data on post-transplant gilteritinib resumption in relapsed or refractory FLT3m+ AML -- Findings from the Phase 3 MORPHO trial in the post-transplant maintenance setting and Phase 1/2 VICEROY trial in newly diagnosed disease highlight how treatment timing, sequen...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
RAPP
LISTED
NASDAQ
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
News Preview
Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, along with consistent efficacy data regardless of patients’ disease severity ...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
XOMA
LISTED
NASDAQ
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc
News Preview
EMERYVILLE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA), the biotech royalty aggregator, today announced it has successfully completed its previously announced acquisition of the entire issued and to be issued share capital of Mural Oncology plc (“Mural”) (Nasdaq: MURA) (the “Acquisition”) pu...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
XENE
LISTED
NASDAQ
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025
News Preview
VANCOUVER, British Columbia and BOSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced new data highlighting its commitment in ep...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
BIIB
LISTED
NASDAQ
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
News Preview
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in seizure-free days, in addition to improvements in cognition, behavior and quality of life—...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2025
CNMD
LISTED
NYSE
CONMED Corporation Announces Strategic Exit from Gastroenterology Product Lines
News Preview
CONMED Corporation (NYSE: CNMD) today announced its intention to exit its gastroenterology product lines as part of its broader portfolio optimization strategy. This exit allows CONMED to fully align operations and resources within its core markets—minimally invasive, robotic, and laparoscopic surgery, smoke evacuation, and the surgical treatment...
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2025
INTS
LISTED
NASDAQ
Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
News Preview
SHELTON, Conn., Dec. 5, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
CGON
LISTED
NASDAQ
New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer
News Preview
IRVINE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced topline data from BOND-003 Cohort P and first results from CORE-008 Cohort...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
LXRX
LISTED
NASDAQ
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum
News Preview
THE WOODLANDS, Texas, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced clinical data on adipose tissue distribution in non-diabetic patients treated with sotagliflozin will be presented at the 22nd Global Cardio Vascular Clinical Trialists Forum (CVCT 2025). The conference is being held December 8-10, 2025,...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
URGN
LISTED
NASDAQ
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
PRINCETON, N.J., Dec. 05, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 14 new employees in connection with their employment with...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
AMRX
LISTED
NASDAQ
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease
News Preview
BRIDGEWATER, N.J., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced new positive interim results from its ongoing Phase 4 ELEVATE-PD study, presented at the Parkinson’s Study Group (PSG) Annual Meeting....
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
ITRM
LISTED
NASDAQ
Iterum Therapeutics Provides Business Update
News Preview
DUBLIN and CHICAGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a business update....
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2025
VRDN
LISTED
NASDAQ
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company’s Board of Directors, made up entirely of independent directors, approved the grant of non-qual...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2025
NTRA
LISTED
NASDAQ
Natera Acquires Foresight Diagnostics
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, today announced that Natera has completed a transaction to acquire Foresight.
Foresight is a cancer diagnostics company and CLIA-registered laboratory. The company’...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2025
PLTR
LISTED
NASDAQ
Palantir and TWG AI Team with NVIDIA to Power Teton Ridge’s Push to Enhance Rodeo with Edge AI
News Preview
Palantir (NASDAQ: PLTR) and TWG AI today announced a new effort with Teton Ridge, the western sports and entertainment company backed by TWG Global, to bring real-time AI and computer vision to rodeo — accelerating and elevating the sport experience for athletes, fans, and partners, in collaboration with NVIDIA.
Over the past year, Teton Ridge, o...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
MURA
LISTED
NASDAQ
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
News Preview
WALTHAM, Mass. and DUBLIN, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“Mural”) announces that the scheme of arrangement between Mural and its shareholders under Chapter 1 of Part 9 of the Companies Act 2014 (the “Scheme”) pursuant to which XRA 5 Corp. (“Sub”), a wholly-owned subsidiary of XOMA Royalty Corporation (Nasda...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
BMEA
LISTED
NASDAQ
Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
News Preview
Durable Glycemic and C-Peptide Improvements with Icovamenib in Insulin-Deficient Type 2 Diabetes Durable Glycemic and C-Peptide Improvements with Icovamenib in Insulin-Deficient Type 2 Diabetes...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
OCUL
LISTED
NASDAQ
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BEDFORD, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to eight newly hired non-executive employees. The awards were made as an inducement material to each recip...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
INMB
LISTED
NASDAQ
Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform
News Preview
Boca Raton, FL, Dec. 05, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INmune” or the “Company”), a clinical-stage inflammation and immunology company, announces a recently published overview of future applications and research areas for mesenchymal stromal cell (MSC) therapies, such as INmune’s CORDStrom™ platform. The article, tit...
Themefolio
Profiler
Peergroup
© Newsfile
05.12.2025
HBFG
LISTED
CSE
Happy Belly Food Group's Heal Wellness QSR Announces the Grand Opening of Their First Atlantic Canada Location in PEI
News Preview
Toronto, Ontario--(Newsfile Corp. - December 5, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands is pleased to announce the grand opening of Heal Wellness ("Heal") in Charlottetown, Prince Edward Island this Saturday, December 6th, 2025. This newe...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2025
OGI
LISTED
NASDAQ
Organigram to Report Fourth Quarter Fiscal 2025 Results on December 16, 2025
News Preview
Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share1, announced today it will report earnings results for its fourth quarter fiscal 2025 ended September 30, 2025, on Tuesday, December 16, 2025, prior to market open.
The Company will host a conference call to discuss its re...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
CAPR
LISTED
NASDAQ
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
News Preview
SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the pricing of its underwritten public offering of 6,000,000 shares of common stock at a public offering price of $25.00 per share. Capricor also granted th...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
05.12.2025
MAJI
LISTED
OTC
Exousia Pro, Inc. Revolutionizes Nutraceuticals With Launch Of Maxasome(TM): The First All-Natural, Biologically Active Exosomal Supplement
News Preview
ORLANDO, FLORIDA / ACCESS Newswire / December 5, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company leveraging proprietary exosome-based delivery systems, today announced the highly anticipated market launch of its flagship nutraceutical, Maxasome™. Derived exclusively from 100% pure Exosome-Like Nanoparticles (ELNs...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
05.12.2025
MDCE
LISTED
OTC
Medical Care Technologies Inc. (OTC Pink:MDCE) Closes Reg A - Dilution Ends, Growth Phase Begins
News Preview
MESA, ARIZONA / ACCESS Newswire / December 5, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE) is pleased to announce that its Regulation A Tier 1 Offering will formally conclude on December 6, 2025, marking a major milestone in the Company's corporate transition and strengthening its capital structure. With the completion of the offering, no...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
05.12.2025
CLDI
LISTED
XASE
Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
News Preview
ORLANDO, FLORIDA / ACCESS Newswire / December 5, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Nova Minerals Limited (Nasdaq:NVA) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, December 6, at 7 p.m. Eastern Time (ET). Bloomberg TV is av...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2025
GALD
LISTED
XWSX
Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body
News Preview
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its certification under the EU Medical Device Regulation (MDR). This expands Sculptra’s current clinical use on the face, to include four new areas: gluteal area, posterior thighs,...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
ORIC
LISTED
NASDAQ
ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025
News Preview
Systemic activity of 35% ORR in 2L+ patients, including in patients with active brain metastases...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
IPN
LISTED
EURONEXT
Ipsen provides update on legacy of Henri Beaufour
News Preview
PARIS, FRANCE, 5 December 2025, Ipsen (Euronext: IPN; ADR: IPSEY) has been informed that the shares of Beech Tree will be transferred to the Alasol Foundation, in accordance with the wishes of Mr. Henri Beaufour, Ipsen’s Board Member and a representative of the founding family who passed away on November 28, 2025. This transfer is expected to take...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
TARA
LISTED
NASDAQ
Protara Announces Pricing of $75 Million Public Offering
News Preview
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the pricing of its underwritten public offering of 13,043,479 shares of its common stock at a price to the public of $5.75 pe...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
ORIC
LISTED
NASDAQ
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025
News Preview
Highly differentiated 1L EGFR PACC preliminary systemic activity of 80% ORR and 100% intracranial ORR, including in patients with active brain metastases...
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2025
A
LISTED
NYSE
Agilent and Monash University Malaysia Mark 15-Year Partnership with New BioDiscovery Hub to Drive Regional Biotech Innovation
News Preview
Collaboration aimed at accelerating R&D in both small- and large-molecule analysis and building high-impact capabilities in fast-growing Asian marketsKUALA LUMPUR, Malaysia, Dec. 5, 2025 /PRNewswire/ -- Agilent Technologies Inc. (NYSE: A) announced the expansion of their strategic collaboration with Monash University in Malaysia to establish a...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2025
BMY
LISTED
NYSE
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) who have receive...
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2025
1801
LISTED
HKSE
Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies
News Preview
SAN FRANCISCO and SUZHOU, China, Dec. 4, 2025 /PRNewswire/ -- Innovent Biologics (HKEX: 01801) today announced that the global strategic collaboration with Takeda (TSE: 4502, NYSE: TAK) has closed and become effective following the satisfaction of all closing conditions. The collaboration, initially announced on October 22, 2025, aims to accelerat...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
6855
LISTED
HKSE
Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA
News Preview
ROCKVILLE, Md. and SUZHOU, China, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced tha...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
KEQU
LISTED
NASDAQ
Kewaunee Scientific Announces Successful Debt Refinancing and Full Repayment of Seller Notes From the Company's Acquisition of Nu Aire, Inc.
News Preview
STATESVILLE, N.C., Dec. 4, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU), a recognized leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products, today announced its successful debt refinancing and the full repayment of its Seller Notes....
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
MDT
LISTED
NYSE
Medtronic announces cash dividend for third quarter of fiscal year 2026
News Preview
GALWAY, Ireland, Dec. 4, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE: MDT) on Thursday, December 4, 2025, approved the company's cash dividend for the third quarter of fiscal year 2026 of $0.71 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2025...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2025
DNTL
LISTED
TSX
Dentalcorp Securityholders Approve Proposed Acquisition by Investment Funds Affiliated with GTCR
News Preview
dentalcorp Holdings Ltd. (“Dentalcorp” or the “Company”) (TSX: DNTL) is pleased to announce that, at the special meeting of the Company’s securityholders (the "Securityholders”) held on December 4, 2025, Securityholders approved the special resolution (the “Arrangement Resolution”) approving the previously announced plan of arrangement whereby a n...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
VNDA
LISTED
NASDAQ
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness
News Preview
WASHINGTON, Dec. 4, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on protocol VP-VLY-686-3403, which until today limited the protocol to a maximum of 90 doses of tradipitant....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2025
XENE
LISTED
NASDAQ
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
VANCOUVER, British Columbia and BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to five new non-...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
AVTR
LISTED
NYSE
Avantor® Appoints Sanjeev Mehra to its Board of Directors
News Preview
RADNOR, Pa., Dec. 4, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Sanjeev Mehra to its Board of Directors, effective immediately. ...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2025
MRM
LISTED
NASDAQ
MEDIROM Mother Labs Partners with TD SYNNEX to Accelerate National Adoption of "MOTHER Bracelet" and "REMONY"
News Preview
TOKYO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) today announced that its subsidiary, MEDIROM MOTHER Labs Inc. (“MOTHER Labs”), which develops health-tech solutions, has entered into a distributor agreement (the “Agreement”) with TD SYNNEX K.K. (“TD SYNNEX”)....
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2025
BAX
LISTED
NYSE
Baxter Announces Pricing of Tender Offers for 2.600% Senior Notes Due 2026 and 1.915% Senior Notes Due 2027
News Preview
Baxter International Inc. (NYSE:BAX) (“Baxter” or the “Company”) today announced the consideration payable in connection with the previously announced cash tender offers for the 2026 Notes and 2027 Notes (each as defined below). The table below sets forth the Total Consideration (as defined below) for each series of Notes.
Title of
Security...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
